The joint prevention and control mechanism of the State Council recently held a press conference to systematically respond to issues related to vaccination. Zeng Yixin, deputy director of the National Health Commission, said that up to now, 31 provinces (autonomous regions and municipalities) and Xinjiang production and Construction Corps have reported a cumulative coverage of 92.1% of the first dose of covid-19 vaccine, 89.7% of the whole course of vaccination, and 71.7% of the enhanced vaccination. "The current party and state leaders in China have completed covid-19 vaccination, and the vaccinations are all domestic vaccines." Zeng Yixin said that this fully shows that Chinese leaders attach great importance to epidemic prevention and control and have high trust in covid-19 vaccine produced in China. Wang Fusheng, director of the infectious diseases department of the fifth medical center of the PLA General Hospital and academician of the Chinese Academy of Sciences, said that various substances in the vaccine are safe for human body and will not directly cause disease. The reagents used in the production of vaccines have been strictly verified by relevant institutions and meet the standards. At present, China has the largest number of covid-19 inactivated vaccine, which has sufficient safety guarantee and has been recognized by international organizations. Fengzijian, executive vice president and Secretary General of the Chinese Preventive Medicine Association, said that at present, the research and development of univalent and multivalent Omicron variant vaccine has been carried out in many technical routes in China. It is reported that the inactivated monovalent Omicron variant vaccine, which has made rapid progress, has been approved for clinical trials and is being carried out in Zhejiang, Hunan, Hong Kong and other places. The Tetravalent Recombinant Protein vaccine, which has made rapid progress, has been approved for phase III clinical trials in the United Arab Emirates, and relevant research has been launched. In addition, the research on broad-spectrum covid-19 vaccine has been arranged. The vaccine that has made rapid progress has been approved for clinical trials, and relevant research has been launched. "The vaccine in China still has a good protective effect on severe cases and deaths caused by the Omicron variant." Feng Zijian said that the research and development of the Omicron variant vaccine in China is progressing steadily and rapidly. As long as there is a need, in accordance with the requirements of relevant regulations, the emergency use procedure can be quickly started to provide vaccination. As for whether it is necessary to vaccinate and when to vaccinate a vaccine specifically targeting the Omicron variant, this problem is being studied not only in China, but also internationally, mainly to study and judge the situation of virus mutation and immune escape. Zhengzhongwei, director of the science and technology development center of the National Health Commission and head of the vaccine research and development team of the scientific research team, said that whether homologous enhanced vaccination (enhanced vaccination with the same technical route) or sequential enhanced vaccination (enhanced vaccination with approved different technical routes) can significantly improve the protective effect of covid-19 vaccine. In response to the question about vaccine dose selection, Wang Junzhi, deputy leader of the expert group of the vaccine research and development special class of the scientific research group of the joint prevention and control mechanism of the State Council and academician of the Chinese Academy of engineering, said that the data of animal protection experiments and human clinical trials during the research and development of covid-19 vaccine in China showed that the safety index of inactivated vaccine was very good when the dose was 3 micrograms to 5 micrograms, the positive conversion rate of antibody was close to 100%, and the antibody titer also reached the expected level, In other words, its safety indicators and effectiveness indicators meet the national standards. (outlook new era)